Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of Its Avenova Brand

Businesswire11/15 21:00

Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)

Benzinga11/12 01:44

NovaBay GAAP EPS of -$0.60 Misses by $0.30, Revenue of $2.44M Misses by $0.19M

Seeking Alpha11/08 13:01

ノヴァベイ ファーマシューティカルズ | 10-Q：Q3 2024 四半期報告書

SEC11/08 05:20

Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q3 Revenue $2.4M

MT Newswires11/08 05:11

NovaBay: Increased the Base Purchase Price for the Company's Eyecare Business From $9.5M to $11.5M >NBY

Dow Jones11/07 05:20